Crestor Gets Advisory Committee For Preventing Cardiovascular Events
This article was originally published in The Pink Sheet Daily
Executive Summary
If AstraZeneca gets JUPITER results on label, it could improve reimbursement for the indication in patients with healthy cholesterol levels but biomarker for inflammation and at least one CVD risk factor.